NASDAQ · Medical - Instruments & Supplies
ATRC (ATRC) Stock
$38.72
+2.54%
NASDAQ: ATRC
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
AtriCure to Announce Second Quarter 2026 Financial Results
Business Wire · Jul 2, 2026
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
MedTech Dive · Jun 29, 2026
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
Zacks · Jun 19, 2026
Do Options Traders Know Something About AtriCure Stock We Don't?
Zacks · Jun 11, 2026
A Look At AtriCure (ATRC) Valuation As BoxX NoAF Trial Acceleration Draws Investor Attention
Simply Wall St. · Jun 7, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.86%
Institutions Held102.21%
Institutions Float Held106.31%
Peer Comparison
About ATRC
ATRC is led by CEO Michael H. Carrel, employs 1,300 people, headquartered in US, publicly traded since 2005.
ATRC stock trades at $38.72 with a market capitalization of $1.97B. The stock is valued at a price-to-earnings (P/E) ratio of 80.24, price-to-book of 2.88, price-to-sales of 2.57. Over the past 52 weeks the stock has ranged between $25.36 and $43.18, and currently trades 10.3% below its 52-week high.
On profitability, ATRC generates a return on equity (ROE) of -0.97%, return on capital employed of -0.61%, an operating margin of -0.36%, a net profit margin of -0.83%.